Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Non-Current Liabilities (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $54.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 7.41% to $54.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $54.7 million, a 7.41% increase, with the full-year FY2024 number at $49.6 million, up 56.45% from a year prior.
  • Total Non-Current Liabilities was $54.7 million for Q3 2025 at 4D Molecular Therapeutics, up from $52.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $54.7 million in Q3 2025 to a low of $12.4 million in Q2 2021.
  • A 5-year average of $33.5 million and a median of $30.3 million in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 143.15% in 2022, then fell 12.68% in 2023.
  • 4D Molecular Therapeutics' Total Non-Current Liabilities stood at $34.2 million in 2021, then dropped by 11.32% to $30.3 million in 2022, then grew by 4.61% to $31.7 million in 2023, then surged by 56.45% to $49.6 million in 2024, then grew by 10.22% to $54.7 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Total Non-Current Liabilities are $54.7 million (Q3 2025), $52.4 million (Q2 2025), and $45.7 million (Q1 2025).